These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17379102)

  • 1. Novel therapeutic agents in acute myeloid leukemia.
    Stone RM
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):163-6. PubMed ID: 17379102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
    Morgan MA; Reuter CW
    Ann Hematol; 2006 Mar; 85(3):139-63. PubMed ID: 16391911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New agents for the treatment of acute myeloid leukemia.
    Tallman MS
    Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia.
    Stone RM; O'Donnell MR; Sekeres MA
    Hematology Am Soc Hematol Educ Program; 2004; ():98-117. PubMed ID: 15561679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep.
    Woods WG
    Pediatr Blood Cancer; 2006 May; 46(5):565-9. PubMed ID: 16261562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
    Ferrara F
    Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Allogeneic stem cell transplantation in the management of acute myeloid leukemia].
    Schmid C; Kolb HJ
    Med Klin (Munich); 2007 Apr; 102(4):317-23. PubMed ID: 17426935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.
    Oliansky DM; Rizzo JD; Aplan PD; Arceci RJ; Leone L; Ravindranath Y; Sanders JE; Smith FO; Wilmot F; McCarthy PL; Hahn T
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):1-25. PubMed ID: 17222748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
    Reikvam H; Kittang AO; Melve G; Mosevoll KA; Bentsen PT; Ersvær E; Gjertsen BT; Bruserud Ø
    Curr Cancer Drug Targets; 2013 Jan; 13(1):30-47. PubMed ID: 22873213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myelogenous leukemia.
    Shipley JL; Butera JN
    Exp Hematol; 2009 Jun; 37(6):649-58. PubMed ID: 19463767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic mechanisms in AML - a target for therapy.
    Oki Y; Issa JP
    Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New agents in myelodysplastic syndromes.
    Jabbour EJ; Giles FJ
    Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted agents in AML: much more to do.
    Stone RM
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):39-48. PubMed ID: 17336253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients.
    Wierzbowska A; Robak T; Krawczyńska A; Pluta A; Wrzesień-Kuś A; Cebula B; Robak E; Smolewski P
    Ann Hematol; 2008 Feb; 87(2):97-106. PubMed ID: 17849117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment for relapsed acute myeloid leukemia: what is new?
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2012 Mar; 19(2):89-94. PubMed ID: 22227525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Lekakis L; de Lima M
    Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.
    Kuendgen A; Germing U
    Cancer Treat Rev; 2009 Apr; 35(2):97-120. PubMed ID: 18951721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.